AICAR
AICAR is an AMP-activated protein kinase (AMPK) activator studied in cell and animal models as an 'exercise mimetic' for its effects on glucose and fat metabolism; it has essentially no human trial data for metabolic, weight-loss, or longevity purposes, though its prodrug (acadesine) was historically tested in humans for an unrelated purpose — cardioprotection during heart surgery.
This page is a research-orientation summary, not a dosing guide. For anything beyond general background, read the primary literature or talk to a qualified clinician — specifics like amount, frequency, or administration aren't something we publish here.
What it does & how it works
AICAR (5-aminoimidazole-4-carboxamide ribonucleotide) is taken up by cells and phosphorylated to ZMP, a nucleotide that mimics AMP and allosterically activates AMPK, a central cellular energy sensor. Activated AMPK promotes glucose uptake, fatty-acid oxidation, and mitochondrial biogenesis, and can increase expression of genes governing oxidative metabolism in skeletal muscle, which is part of why it has been studied alongside PPAR-delta agonists as an 'exercise in a pill' combination in mice. A 2021 systematic review noted, however, that many of AICAR's reported effects occur independently of AMPK, through ZMP's actions on other AMP-sensitive enzymes, which complicates simple mechanistic claims about the compound.
Typical results seen in research
In sedentary mice, combined treatment with AICAR and a PPAR-delta agonist increased treadmill running endurance without any exercise training, and AICAR alone has produced transient improvements in some measures of rodent brain function and metabolic gene expression. These findings are confined to cell and animal models — there is no published human trial evidence that AICAR itself improves body composition, endurance, or longevity in people, and the compound is banned by the World Anti-Doping Agency because of its performance-enhancing potential observed in animal studies.
How it’s commonly used
AICAR is used only in laboratory and preclinical research settings, administered to animals typically by injection; it is not an approved drug for any metabolic, weight-loss, or performance indication in humans. Its prodrug, acadesine, was studied in humans via intravenous administration in a different clinical context (cardiac surgery cardioprotection trials), but that historical use is unrelated to how AICAR is marketed today for metabolic or longevity purposes, and no validated human protocol exists for those uses.
- Cell · 2008 AMPK and PPARdelta agonists are exercise mimetics
- Cells · 2021 AICAr, a Widely Used AMPK Activator with Important AMPK-Independent Effects: A Systematic Review
- Oncotarget · 2015 Exercise-mimetic AICAR transiently benefits brain function
Curated from published literature for research orientation. Not an exhaustive review, and not a substitute for reading primary sources.